Innovative Diagnostic Platform Primera Dx offers a next-generation molecular diagnostics platform that combines PCR with capillary electrophoresis, providing highly multiplexed and quantitative diagnostic answers which are highly adaptable for clinical laboratory needs and pharmaceutical collaboration opportunities.

Targeted Market Expansion The company's dual strategy focuses on selling its open platform to clinical labs and partnering with pharmaceutical firms for developing high-value companion diagnostics, opening multiple avenues for sales growth across both laboratory and pharmaceutical markets.

Technological Edge Primera Dx’s ability to easily design complex multi-modal assays for various biomarker types positions it as a versatile solution for labs seeking advanced, customizable testing options, creating potential upsell and repeat business opportunities.

Growth Potential With annual revenue between 1M and 10M and a specialized niche in molecular diagnostics, Primera Dx can target mid-sized laboratories and biotech companies seeking innovative testing platforms, expanding its customer base.

Strategic Partnerships Collaborations with pharmaceutical companies for companion diagnostics can accelerate product adoption and provide B2B sales opportunities, especially as personalized medicine continues to grow in relevance within the healthcare industry.